RBC Capital: 'What's Regeneron Pharma's (REGN) Best Next Move'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall Street set to open lower as high-stakes Iran, inflation tests loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Hungarian Gripen jet crashes, no injuries reported, PM Magyar says
- Wall Street set to open lower as high-stakes Iran, inflation tests loom
RBC Capital Reiterates Sector Perform Rating on Regeneron Pharma (REGN)
June 4, 2025 5:09 AM EDTRBC Capital analyst Brian Abrahams reiterated a Sector Perform rating and $662.00 price target on Regeneron Pharma (NASDAQ: REGN).
The analyst comments "Our view: In parallel with our report on potential next steps for REGN following the itepekimab setback, we conducted a flash... More
